Phase II trial of NNZ 2566 for autism spectrum disorders and neurodevelopmental disorders.

Trial Profile

Phase II trial of NNZ 2566 for autism spectrum disorders and neurodevelopmental disorders.

Planning
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2012

At a glance

  • Drugs Trofinetide (Primary)
  • Indications Developmental disabilities; Pervasive child development disorders
  • Focus Therapeutic Use
  • Sponsors Neuren Pharmaceuticals
  • Most Recent Events

    • 07 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top